Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY)

OTCMKTS · Delayed Price · Currency is USD
16.42
+0.63 (3.96%)
Jul 11, 2025, 9:30 AM EDT
17.75%
Market Cap12.54B
Revenue (ttm)2.61B
Net Income (ttm)451.74M
Shares Outn/a
EPS (ttm)2.16
PE Ratio27.76
Forward PE16.06
Dividend0.19 (1.16%)
Ex-Dividend DateMay 20, 2025
Volume202
Average Volume522
Open16.42
Previous Close15.80
Day's Range16.42 - 16.42
52-Week Range12.40 - 16.42
Beta0.52
RSI60.50
Earnings DateJul 29, 2025

About RICFY

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due ... [Read more]

Sector Healthcare
Founded 1926
Employees 4,583
Stock Exchange OTCMKTS
Ticker Symbol RICFY
Full Company Profile

Financial Performance

In 2024, RICFY's revenue was 2.34 billion, an increase of 12.45% compared to the previous year's 2.08 billion. Earnings were 416.51 million, an increase of 7.01%.

Financial numbers in EUR Financial Statements

News

There is no news available yet.